版本:
中国

Lilly's breast cancer drug combination succeeds in key study

March 20 U.S. drugmaker Eli Lilly and Co said on Monday a combination of its experimental breast cancer drug and chemotherapy slowed disease progression in patients who had relapsed or did not derive enough benefit from prior treatment.

Lilly's drug is from the same new class of breast cancer treatments as Pfizer Inc's recently approved drug, Ibrance. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐